Overview

Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether zolendronic acid, a third generation bisphosphonate, is effective in preventing bone loss in the first year after kidney transplantation.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Sao Paulo General Hospital
Treatments:
Diphosphonates
Vitamin D
Vitamins
Zoledronic Acid
Criteria
Inclusion Criteria:

- All adult kidney transplant recipients who were stable perioperative and able to
return for regular follow-up

Exclusion Criteria:

- Glomerular filtration rate < 30 ml/min/1.73m² one week after transplantation

- Previous parathyroidectomy or diagnosis of adynamic bone disease (with bone biopsy)